ELISA IVD Test Noninvasively Diagnoses Bladder Cancer with Unprecedented Accuracy

6 per 100,000 and a mortality rate of 3.2 per 100,000 in the male population. Typically, patients with bladder cancer initially experience painless macroscopic hematuria - blood in the urine. Those presenting with hematuria often face the challenging decision of undergoing a cystoscopy, the gold standard in bladder cancer diagnosis, to confirm the presence of the disease and assess its extent if a lesion is suspected. Treatment options for bladder cancer vary depending on the risk category and the extent of muscle invasion. Regular follow-ups for non-muscle invasive bladder cancer usually involve urinary cytology and cystoscopy at intervals of three to six months for the first two years, then every six months up to five years, and annually thereafter.

BioCheetah Pte. Ltd. (Singapore) is revolutionizing the approach to bladder cancer diagnosis and patient follow-up by introducing innovative biomarkers for more efficient, non-invasive diagnostic and monitoring procedures. This new approach aims to overcome the limitations in early detection and ongoing surveillance of bladder cancer. BioCheetah's leading product, the VECanDx ELISA Test, is designed for non-invasive bladder cancer detection in patients with hematuria and those with recurrent bladder cancer.

BioCheetah’s ELISA IVD test utilizes the enzyme-linked immunosorbent assay (ELISA), which is routinely used in hospitals for identifying and quantifying disease-specific biomarkers from patient samples. The VECanDx ELISA Test leverages this standard procedure for the sensitive detection of five patented bladder cancer biomarkers. By employing immunoassays that target five unique protein biomarkers exclusive to bladder cancer, BioCheetah's multiplex biomarker panel offers exceptional accuracy in diagnosing bladder cancer, presenting a new, non-invasive option for detecting the disease in patients.

Related Links:
BioCheetah Pte Ltd.